Invesco’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Invesco’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-35,244	Closed	-$148K	–	4047
2023 Q1	$148K	Buy	35,244 +392	+1%	+$2.04K	﹤0.01%	3667
2022 Q4	$209K	Sell	34,852 -502,031	-94%	-$2.74M	﹤0.01%	3668
2022 Q3	$3.13M	Sell	536,883 -843,023	-61%	-$5.25M	﹤0.01%	2446
2022 Q2	$8.24M	Sell	1,379,906 -23,708	-2%	-$121K	﹤0.01%	1978
2022 Q1	$6.55M	Buy	+1,403,614	New	+$4.19M	﹤0.01%	2234
2019 Q1	–	Sell	-17,276	Closed	-$13K	–	3975
2018 Q4	$13K	Buy	17,276 +27	+0.2%	+$44	﹤0.01%	3773
2018 Q3	$37K	Sell	17,249 -384	-2%	-$951	﹤0.01%	3831
2018 Q2	$88K	Buy	+17,633	New	+$77.2K	﹤0.01%	3784
2015 Q3	–	Sell	-246	Closed	-$5K	–	4295
2015 Q2	$5K	Buy	+246	New	+$4.75K	﹤0.01%	4266
2014 Q2	–	Sell	-68,935	Closed	-$2.34M	–	4167
2014 Q1	$2.34M	Buy	+68,935	New	+$2.36M	﹤0.01%	2463

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Invesco's CTIC Position: Q2 2023 in Review

Invesco sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 35,244 shares — an estimated $148K sold.

Invesco first reported a position in CTIC in Q1 2014 and held it in 10 quarters. The position peaked at $8.24M in Q2 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Invesco reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Invesco sold 35,244 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $148K.
Invesco first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2014 and held it in 10 quarters.
Invesco's CTI BioPharma Corp. (DE) Common Stock position peaked at $8.24M in Q2 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Invesco's 13F filing for Q2 2023, filed 11 Aug 2023.